Journal Information
Vol. 47. Issue 5.
Pages 222-223 (January 2011)
Vol. 47. Issue 5.
Pages 222-223 (January 2011)
Editorial
Full text access
Arguments in Favor of Corticosteroids in Pneumonia
Corticoides en la neumonía: argumentos a favor
Visits
5535
Oriol Sibila
Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
This item has received
Article information
Full text is only aviable in PDF
References
[1]
H.N. Wagner, I.L. Bennet, L. Lasagna, L.E. Cluff, M.B. Rosenthal, G.S. Mirick.
The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicilin.
Bull Johns Hopkins Hosp, 98 (1956), pp. 197-215
[2]
D. Snijders, J.M.A. Daniels, C. De Graaff, T. Van der Werf, W. Boersma.
Efficacy of corticoesteroids in community-acquired pneumonia. A Randomized double-blinded clinical trial.
Am J Respir Crit Care Med, 181 (2010), pp. 975-982
[3]
L.A. Díaz, E.M. Mortensen, A. Anzueto, M.I. Restrepo.
Novel targets in the manegement of pneumonia.
Ther Adv Respir Dis, 2 (2008), pp. 387-400
[4]
J.P. Mizgerd.
Acute lower respiratory tract infection.
N Engl J Med, 14 (2008), pp. 716-727
[5]
R. Menéndez, M. Cavalcanti, S. Reyes, J. Mensa, R. Martinez, M.A. Marcos, et al.
Markers of treatment failure in hospitalised community-acquired pneumonia.
Thorax, 63 (2008), pp. 447-452
[6]
R. Menéndez, R. Martínez, S. Reyes, J. Mensa, X. Filella, M.A. Marcos, et al.
Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
Thorax, 64 (2009), pp. 587-591
[7]
R. Martínez, R. Menéndez, S. Reyes, E. Polverino, C. Cilloniz, A. Martínez, et al.
Factors associated with inflammatory cytokine patterns in community-acquired pneumonia.
Eur Respir J, 37 (2010), pp. 393-399
[8]
B.G. Cosio, A. Torrego, I.M. Adckock.
Molecular mechanisms of glucocorticoids.
Arch Bronconeumol, 41 (2005), pp. 34-41
[9]
T. Rhen, J.A. Cidlowski.
Antiinflammatory action of glucocorticoids – new mechanisms for old drugs.
N Engl J Med, 20 (2005), pp. 1711-1723
[10]
C. Montón, S. Ewig, A. Torres, M. El-Ebiary, X. Filella, A. Rañó, et al.
Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study.
Eur Respir J, 14 (1999), pp. 218-220
[11]
C. Agustí, A. Rañó, X. Filella, J. González, A. Moreno, A. Xaubet, et al.
Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment. Etiology, prognostic factors and associated inflammatory response.
Chest, 123 (2003), pp. 488-498
[12]
O. Sibila, C.M. Luna, C. Agustí, S. Baquero, S. Gando, J.R. Patrón, et al.
Effects of glucocorticoids in ventilated piglets with severe pneumonia.
Eur Respi J, 32 (2008), pp. 1037-1046
[13]
G.U. Meduri, S. Kanangat, M. Bronze, D.R. Patterson, C.U. Meduri, C. Pak, et al.
Effects of methylprednisolone on intracellular bacterial growth.
Clin Diagn Lab Immunol, 8 (2001), pp. 1156-1163
[14]
Y. Li, X. Cui, X. Li, S.B. Solomon, R.L. Danner, S.M. Banks, et al.
Risk of death not alter the efficacy of hydrocortisone therapy in a mouse E. Coli pneumonia model. Risk and corticoesteroids in sepsis.
Intensive Care Med, 34 (2008), pp. 568-577
[15]
R. Confalonieri, G. Rubino, A. Potena, M. Piatella, P. Parigi, G. Puccio, et al.
Hydrocortisone infusion for severe community-acquired pneumonia;a preliminar randomised study.
Am J Respir Crit Care Med, 171 (2005), pp. 242-248
[16]
C. García-Vidal, E. Calbo, V. Pascual, C. Ferrer, S. Quintana, J. Garau.
Effects of systemic steroids in patients with severe community-acquired pneumonia.
Eur Respir J, 30 (2007), pp. 951-956
[17]
D. Annane, E. Bellissant, P.E. Bollaert, J. Briegel, M. Confalonieri, R. De Gaudio, et al.
Corticoesteroids in the treatment of severe sepsis and septic shock in adults. A systematic review.
JAMA, 301 (2009), pp. 2362-2375
[18]
M.J. Fine, T.E. Auble, D.M. Yealey, B.H. Hanusu, L.A. Weissfeld, D.E. Singer, et al.
A prediction rule to identify low-risk patients with community-acquired pneumonia.
N Eng J Med, 336 (1997), pp. 243-250
[19]
R. Menéndez, A. Torres, F. Rodríguez de Castro, R. Zalacain, J. Aspa, J.J. Martín Villasclaras, et al.
Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.
Thorax, 59 (2004), pp. 960-965
[20]
A. Torres, R. Menéndez.
Mortality in COPD patients with community-acquired pneumonia. Who is the third partner?.
Eur Respir J, 28 (2006), pp. 262-263
Copyright © 2011. Sociedad Española de Neumología y Cirugía Torácica